Abstract:IL-27 has been shown to play a suppressive role in experimental autoimmunc encephalomyelitis (EAE) as demonstrated by more severe disease in IL-2711-deficient (WSX-1(-/-)) mice. However, whether IL-27 influences the induction or effector phase of EAE is unknown. This is an important question as therapies for autoimmune diseases are generally started after autoreactive T cells have been primed. In this study, we demonstrate maximal gene expression of IL-27 subunits and its receptor in the CNS at the effector phases of relapsing-remitting EAE including disease peak and onset of relapse. We also show that activated astrocyte cultures secrete IL-27p28 protein which is augmented by the endogenous factor, IFN-gamma. To investigate functional significance of a correlation between gene expression and disease activity, we examined the effect of IL-27 at the effector phase of disease using adoptive transfer EAE. Exogenous IL-27 potently suppressed the ability of encephalitogenic lymph node and spleen cells to transfer EAE. IL-27 significantly inhibited both nonpolarized and IL-23-driven IL-17 production by myelin-reactive T cells thereby suppressing their encephalitogenicity in adoptive transfer EAE. Furthermore, we demonstrate a strong suppressive effect of IL-27 on active EAE in vivo when delivered by s.c. osmotic pump. IL-27-treated mice had reduced CNS inflammatory infiltration and, notably, a lower proportion of Thl7 cells. Together, these data demonstrate the suppressive effect of IL-27 on primed, autoreactive T cells, particularly, cells of the Thl7 lineage. IL-27 can potently suppress the effector phase of EAE in vivo and, thus, may have therapeutic potential in autnimmune diseases such as multiple sclerosis.

Interleukin-37 Suppresses CNS Autoimmunity by Stimulating an Amphiregulin-IL-10 Axis

IL-37 Suppresses CNS Autoimmunity by Increasing the Frequency of Treg Cells and Reducing CD4 + T Cell-Derived IL-10 Production.

Interleukin-33 is Released in Spinal Cord and Suppresses Experimental Autoimmune Encephalomyelitis in Mice.

Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8

Suppressive Effect of Il-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis

IL-37b Suppresses T Cell Priming by Modulating Dendritic Cell Maturation and Cytokine Production Via Dampening ERK/NF-κB/S6K Signalings

Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4+CD25+ Regulatory T Cells.

Interleukin-27 Suppresses Experimental Autoimmune Encephalomyelitis During Bone Marrow Stromal Cell Treatment

A new target for the treatment of inflammatory bowel disease: Interleukin-37

Insights into the multifaceted role of interleukin-37 on human immune cell regulation

IL-10 Modulates Th17 Pathogenicity during Autoimmune Diseases

Role Of Interleukin-37 In Inflammatory And Autoimmune Diseases

Interleukin-33 from oligodendrocytes sustains effector differentiation of tissue-resident CD8+ T cells and is a druggable target in CNS autoimmune disease

Role of the IL-12/IL-23 System in the Regulation of T-Cell Responses in Central Nervous System Inflammatory Demyelination;

IL-27p28 Inhibits Central Nervous System Autoimmunity by Concurrently Antagonizing Th1 and Th17 Responses

IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease

Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor.

IL-37 Isoform A Prevents Collagen-Induced Arthritis in Mice by Modulating the Th17/Treg Balance via IL1R8 Receptors

IL-37 Represses the Autoimmunity in Myasthenia Gravis Via Directly Targeting Follicular Th and B Cells

Interleukin-1 promotes autoimmune neuroinflammation by suppressing endothelial heme oxygenase-1 at the blood–brain barrier

Insights into IL-37, the role in autoimmune diseases